LTC3412676DI2 - Cikliniai borono rūgšties dariniai, jų gamybos būdas ir terapinis panaudojimas - Google Patents

Cikliniai borono rūgšties dariniai, jų gamybos būdas ir terapinis panaudojimas

Info

Publication number
LTC3412676DI2
LTC3412676DI2 LTPA2020521C LTPA2020521C LTC3412676DI2 LT C3412676D I2 LTC3412676D I2 LT C3412676DI2 LT PA2020521 C LTPA2020521 C LT PA2020521C LT PA2020521 C LTPA2020521 C LT PA2020521C LT C3412676D I2 LTC3412676D I2 LT C3412676DI2
Authority
LT
Lithuania
Prior art keywords
production method
acid derivatives
boronic acid
therapeutic use
cyclic boronic
Prior art date
Application number
LTPA2020521C
Other languages
English (en)
Original Assignee
Melinta Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45565270&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LTC3412676D(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Melinta Therapeutics, Inc. filed Critical Melinta Therapeutics, Inc.
Publication of LTPA2020521I1 publication Critical patent/LTPA2020521I1/lt
Publication of LTC3412676DI2 publication Critical patent/LTC3412676DI2/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
LTPA2020521C 2010-08-10 2020-07-10 Cikliniai borono rūgšties dariniai, jų gamybos būdas ir terapinis panaudojimas LTC3412676DI2 (lt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US37229610P 2010-08-10 2010-08-10
US201161488655P 2011-05-20 2011-05-20
EP11816882.2A EP2603514B1 (en) 2010-08-10 2011-08-08 Cyclic boronic acid ester derivatives and therapeutic uses thereof
PCT/US2011/046957 WO2012021455A1 (en) 2010-08-10 2011-08-08 Cyclic boronic acid ester derivatives and therapeutic uses thereof

Publications (2)

Publication Number Publication Date
LTPA2020521I1 LTPA2020521I1 (lt) 2020-08-10
LTC3412676DI2 true LTC3412676DI2 (lt) 2022-05-10

Family

ID=45565270

Family Applications (3)

Application Number Title Priority Date Filing Date
LTEP18183968.9T LT3412676T (lt) 2010-08-10 2011-08-08 Cikliniai borono rūgšties dariniai, jų gamybos būdas ir terapinis panaudojimas
LTPA2020521C LTC3412676DI2 (lt) 2010-08-10 2020-07-10 Cikliniai borono rūgšties dariniai, jų gamybos būdas ir terapinis panaudojimas
LTPA2020519C LTC3412676I2 (lt) 2010-08-10 2020-07-10 Cikliniai borono rūgšties dariniai, jų gamybos būdas ir terapinis panaudojimas

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LTEP18183968.9T LT3412676T (lt) 2010-08-10 2011-08-08 Cikliniai borono rūgšties dariniai, jų gamybos būdas ir terapinis panaudojimas

Family Applications After (1)

Application Number Title Priority Date Filing Date
LTPA2020519C LTC3412676I2 (lt) 2010-08-10 2020-07-10 Cikliniai borono rūgšties dariniai, jų gamybos būdas ir terapinis panaudojimas

Country Status (29)

Country Link
US (11) US8680136B2 (lt)
EP (3) EP3412676B1 (lt)
JP (4) JP6266978B2 (lt)
KR (3) KR102205755B1 (lt)
CN (1) CN103180328B (lt)
AU (1) AU2011289615B2 (lt)
BR (1) BR112013003045B1 (lt)
CA (1) CA2807546C (lt)
CL (1) CL2013000399A1 (lt)
CO (1) CO6680667A2 (lt)
CY (3) CY1123208T1 (lt)
DK (2) DK3412676T3 (lt)
ES (2) ES2691468T3 (lt)
HR (1) HRP20200741T1 (lt)
HU (4) HUE040086T2 (lt)
IL (1) IL224564A (lt)
LT (3) LT3412676T (lt)
LU (2) LUC00168I2 (lt)
MX (1) MX348653B (lt)
MY (2) MY198204A (lt)
NO (2) NO2019014I1 (lt)
NZ (1) NZ607354A (lt)
PL (2) PL2603514T3 (lt)
PT (2) PT2603514T (lt)
RS (1) RS60310B1 (lt)
RU (1) RU2599791C2 (lt)
SG (1) SG187757A1 (lt)
SM (1) SMT202000248T1 (lt)
WO (1) WO2012021455A1 (lt)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102205755B1 (ko) 2010-08-10 2021-01-22 렘펙스 파머수티클스 인코퍼레이티드 고리형 보론산 에스터 유도체의 결정 형태
WO2013033461A1 (en) * 2011-08-31 2013-03-07 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
US20150119363A1 (en) * 2012-02-15 2015-04-30 Rempex Pharmaceuticals, Inc.. Methods of treating bacterial infections
WO2013134562A1 (en) 2012-03-09 2013-09-12 Inception 2, Inc. Triazolone compounds and uses thereof
US9156858B2 (en) 2012-05-23 2015-10-13 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
US20150238473A1 (en) 2012-09-27 2015-08-27 University Of Rochester Methods and compositions for treating infection
PT2928898T (pt) 2012-12-07 2021-07-05 Venatorx Pharmaceuticals Inc Inibidores de beta-lactamase
CA2894281C (en) 2012-12-20 2021-04-20 Inception 2, Inc. Triazolone compounds and uses thereof
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
JP6324409B2 (ja) * 2013-01-04 2018-05-16 レンペックス・ファーマシューティカルズ・インコーポレイテッド ボロン酸誘導体及びその治療的使用
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
JP2016509594A (ja) 2013-01-04 2016-03-31 レンペックス・ファーマシューティカルズ・インコーポレイテッド ボロン酸誘導体及びその治療的使用
JP6346904B2 (ja) 2013-01-10 2018-06-20 ベナトルクス ファーマシューティカルズ，インク． ベータ−ラクタマーゼ阻害剤
WO2014151958A1 (en) 2013-03-14 2014-09-25 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
JP6142076B2 (ja) * 2013-05-03 2017-06-07 マイクロバイオティックス・インコーポレーテッド 抗微生物性増強剤
EP3041826A4 (en) 2013-09-06 2017-02-15 Inception 2, Inc. Triazolone compounds and uses thereof
FI3604316T3 (fi) * 2014-05-05 2024-02-29 Melinta Therapeutics Inc Boronaattisuolojen synteesi
US9687497B1 (en) 2014-05-05 2017-06-27 Rempex Pharmaceuticals, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
AU2015264418A1 (en) 2014-05-19 2016-11-10 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9511142B2 (en) 2014-06-11 2016-12-06 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
RU2686740C2 (ru) 2014-06-11 2019-04-30 Венаторкс Фармасьютикалс, Инк. Ингибиторы бета-лактамазы
EA201692301A1 (ru) * 2014-07-01 2017-06-30 Ремпекс Фармасьютикалз, Инк. Производные бороновой кислоты и их терапевтическое применение
WO2016081297A1 (en) * 2014-11-18 2016-05-26 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
CN104447610A (zh) * 2014-11-21 2015-03-25 山东金城医药化工股份有限公司 高纯度头孢他啶侧链酸的制备方法
CN107207537B (zh) * 2014-12-19 2019-05-31 莱姆派克斯制药公司 用于生产硼酸衍生物的设备和连续流方法
US20180051041A1 (en) 2015-03-17 2018-02-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
JP6945452B2 (ja) 2015-04-24 2021-10-06 レンペックス・ファーマシューティカルズ・インコーポレイテッド 細菌感染症の処置方法
CN108472284A (zh) 2015-09-11 2018-08-31 维纳拓尔斯制药公司 β-内酰胺酶抑制剂
WO2017100537A1 (en) 2015-12-10 2017-06-15 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
UA124464C2 (uk) 2016-06-30 2021-09-22 Кьюпекс Біофарма, Інк. Похідні боронової кислоти та їх терапевтичні застосування
WO2018027062A1 (en) 2016-08-04 2018-02-08 VenatoRx Pharmaceuticals, Inc. Boron-containing compounds
NZ754364A (en) 2016-12-22 2023-04-28 Calithera Biosciences Inc Compositions and methods for inhibiting arginase activity
KR102768209B1 (ko) 2017-01-09 2025-02-18 멜린타 테라퓨틱스, 엘엘씨 세균 감염을 치료하는 방법
JOP20190188A1 (ar) 2017-02-01 2019-08-01 Rempex Pharmaceuticals Inc جهاز وعملية تدفق مستمرة لإنتاج مشتق حمض بورونيك
ES3015371T3 (en) 2017-03-06 2025-05-05 Venatorx Pharmaceuticals Inc Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof
WO2018218190A1 (en) 2017-05-26 2018-11-29 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
EP3630783A4 (en) 2017-05-26 2021-03-03 Venatorx Pharmaceuticals, Inc. PENICILLIN-BINDING PROTEIN INHIBITORS
JOP20200075A1 (ar) 2017-10-03 2020-04-30 Melinta Therapeutics Inc طرق لعلاج حالات عدوى بكتيرية
EP3694864B1 (en) 2017-10-11 2025-03-05 Qpex Biopharma, Inc. Boronic acid derivatives and synthesis thereof
MX2020004425A (es) 2017-11-01 2020-08-06 Melinta Therapeutics Inc Síntesis de derivados de éster boronato y usos de estos.
WO2019204419A1 (en) 2018-04-20 2019-10-24 The Medicines Company (San Diego), Llc Boronic acid derivatives and therapeutic uses thereof
WO2019226931A1 (en) 2018-05-25 2019-11-28 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
CN111039965B (zh) * 2018-10-12 2020-12-01 新发药业有限公司 一种法硼巴坦的简便制备方法
WO2020112542A1 (en) 2018-11-29 2020-06-04 VenatoRx Pharmaceuticals, Inc. Combination compositions comprising a beta-lactamase inhibitor and uses thereof
AU2021266715A1 (en) 2020-05-05 2022-11-17 Qpex Biopharma, Inc. Boronic acid derivatives and synthesis, polymorphic forms, and therapeutic uses thereof
US20240173374A1 (en) * 2021-02-25 2024-05-30 Ohio State Innovation Foundation Liposomal formulations of boronic acid containing active agents
CN113214302B (zh) * 2021-04-23 2022-06-24 四川大学 一种抑制金属β-内酰胺酶和/或丝氨酸β-内酰胺酶的3-取代五元环状硼酸酯衍生物
WO2023082055A1 (zh) * 2021-11-09 2023-05-19 中国医学科学院医药生物技术研究所 包含β-内酰胺类化合物的药物组合物及其用途
GB202306835D0 (en) 2023-05-09 2023-06-21 Adjutec Pharma As Therapy

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3686398A (en) 1970-07-20 1972-08-22 Chevron Res 10,9-boroxarophenanthrene as fungicides
US4194047A (en) 1975-11-21 1980-03-18 Merck & Co., Inc. Substituted N-methylene derivatives of thienamycin
US4260543A (en) 1978-07-03 1981-04-07 Merck & Co., Inc. Crystalline N-formimidoyl thienamycin
US4409214A (en) 1979-11-19 1983-10-11 Fujisawa Pharmaceutical, Co., Ltd. 7-Acylamino-3-vinylcephalosporanic acid derivatives and processes for the preparation thereof
US4353807A (en) 1981-03-24 1982-10-12 Mobil Oil Corporation Lubricants and fuels containing boroxarophenanthrene compounds
FR2573070B1 (fr) 1984-11-13 1987-01-30 Rhone Poulenc Sante Procede de preparation de composes carbonyles
FR2574070B1 (fr) 1984-11-30 1987-02-27 Stam Catalyseur de prise de mortiers d'anhydrite projetes a la lance, a resistance amelioree a un stockage a temperature et humidite elevees, et utilisation d'un tel catalyseur
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
US4822786A (en) 1986-07-01 1989-04-18 Kaken Pharmaceutical Co., Ltd. Cephalosporin compounds, and antibacterial agents
ZA893284B (en) 1988-05-04 1990-03-28 Igen Inc Peptide analogs and their use as haptens to elicit catalytic antibodies
US5442100A (en) 1992-08-14 1995-08-15 The Procter & Gamble Company β-aminoalkyl and β-N-peptidylaminoalkyl boronic acids
US5888998A (en) 1997-04-24 1999-03-30 Synphar Laboratories, Inc. 2-oxo-1-azetidine sulfonic acid derivatives as potent β-lactamase inhibitors
US6184363B1 (en) 1997-06-13 2001-02-06 Northwestern University Inhibitors of β-lactamases and uses therefor
JP2002504122A (ja) 1997-06-13 2002-02-05 ノースウエスタン ユニバーシティー ベータラクタマーゼ阻害剤及びその使用方法
AU3124300A (en) 1998-12-16 2000-07-03 Northwestern University Inhibitors of beta-lactamases and uses therefor
AU2190400A (en) 1998-12-16 2000-07-03 Northwestern University Inhibitors of beta-lactamases and uses therefor
EP1216239B1 (en) 1999-09-25 2004-02-11 SmithKline Beecham plc Piperazine derivatives as 5-ht1b antagonists
EP1227722A1 (en) 1999-10-28 2002-08-07 Merck & Co., Inc. Novel succinic acid metallo-beta-lactamase inhibitors and their use in treating bacterial infections
WO2002022137A1 (en) 2000-09-12 2002-03-21 Shoichet Brian K β-LACTAM ANALOGS AND USES THEREFOR
PT1322648E (pt) 2000-09-14 2005-11-30 Pantherix Ltd Derivados de acidos 3-(heteroarilacetamido)-2-oxo-azetidina-1-sulfonicos como agentes antibacterianos
WO2002054931A2 (en) 2001-01-10 2002-07-18 Bristol Myers Squibb Company P Alpha-aminoboronic acids prepared by novel synthetic methods
DE10118698A1 (de) 2001-04-17 2002-11-07 Jerini Ag Verfahren zur Immobilisierung und damit hergestellte Anordnungen von Verbindungen auf einer planaren Oberfläche
WO2003057144A2 (en) 2001-12-26 2003-07-17 Guilford Pharmaceuticals Change inhibitors of dipeptidyl peptidase iv
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
JP2003229277A (ja) 2002-02-04 2003-08-15 Matsushita Electric Ind Co Ltd 発光素子材料およびそれを用いた発光素子並びに装置
AUPS065102A0 (en) 2002-02-20 2002-03-14 Unisearch Limited Fluorous acetalation
EP1550657A4 (en) 2002-09-11 2009-12-30 Kureha Corp AMINO COMPOUNDS AND THEIR USE
AU2003268752A1 (en) 2002-10-30 2004-05-25 Sumitomo Chemical Company, Limited High-molecular compounds and polymerer light emitting devices made by using the same
US7439253B2 (en) 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
US7271186B1 (en) 2002-12-09 2007-09-18 Northwestern University Nanomolar β-lactamase inhibitors
US6936638B2 (en) 2002-12-20 2005-08-30 Migenix Corp. Ligands of adenine nucleotide translocase (ANT) and compositions and methods related thereto
TW200418791A (en) 2003-01-23 2004-10-01 Bristol Myers Squibb Co Pharmaceutical compositions for inhibiting proteasome
JP4233365B2 (ja) 2003-03-25 2009-03-04 三井化学株式会社 アザジオール錯体化合物、及び該化合物を用いる光記録媒体
US7842941B2 (en) 2003-10-06 2010-11-30 Sumitomo Chemical Company, Limited Aromatic compound
JP2007508290A (ja) 2003-10-10 2007-04-05 ファイザー・プロダクツ・インク ＧＳＫ−３阻害剤としての置換２Ｈ−［１，２，４］トリアゾロ［４，３−ａ］ピラジン
US7674913B2 (en) 2003-11-12 2010-03-09 Phenomix Corporation Heterocyclic boronic acid compounds
TW200600494A (en) 2004-03-08 2006-01-01 Chugai Pharmaceutical Co Ltd Bisphenyl compounds useful as vitamin d3 receptor agonists
US20060019116A1 (en) 2004-07-22 2006-01-26 Eastman Kodak Company White electroluminescent device with anthracene derivative host
TW200618820A (en) 2004-11-05 2006-06-16 Alza Corp Liposome formulations of boronic acid compounds
US20060178357A1 (en) 2005-02-10 2006-08-10 Buynak John D Chphalosporin-derived mercaptans as inhibitors of serine and metallo-beta-lactamases
SI3424932T1 (sl) * 2005-02-16 2021-08-31 Anacor Pharmaceuticals, Inc. Boronoftalidi za terapevtsko uporabo
TWI353981B (en) 2005-02-22 2011-12-11 Teva Pharma Preparation of rosuvastatin
WO2006101779A2 (en) 2005-03-15 2006-09-28 The University Of Chicago Non-aqueous electrolytes for lithium ion batteries
US7825139B2 (en) 2005-05-25 2010-11-02 Forest Laboratories Holdings Limited (BM) Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
TW200734311A (en) 2005-11-21 2007-09-16 Astrazeneca Ab New compounds
HRP20110841T1 (hr) 2005-12-07 2012-01-31 Basilea Pharmaceutica Ag Korisni monobaktamski antibiotici
HRP20150710T1 (hr) 2006-02-16 2015-08-14 Anacor Pharmaceuticals, Inc. Male molekule koje sadrže bor kao protu-upalni agensi
CA2664296A1 (en) 2006-09-27 2008-04-03 Merck & Co., Inc. Novel inhibitors of beta-lactamase
KR101320718B1 (ko) 2007-03-23 2013-10-21 바실리어 파마슈티카 아게 세균 감염 치료용 조합 약제
GB0719366D0 (en) * 2007-10-03 2007-11-14 Smithkline Beecham Corp Compounds
TW200936143A (en) 2007-11-13 2009-09-01 Protez Pharmaceuticals Inc Beta-lactamase inhibitors
US20100120715A1 (en) 2007-11-13 2010-05-13 Burns Christopher J Beta-lactamase inhibitors
CN101918407B (zh) 2008-01-18 2014-02-26 默沙东公司 β-内酰胺酶抑制剂
US8129398B2 (en) 2008-03-19 2012-03-06 Bristol-Myers Squibb Company HIV integrase inhibitors
US20100256092A1 (en) 2008-05-12 2010-10-07 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
WO2009139834A1 (en) 2008-05-13 2009-11-19 Poniard Pharmaceuticals, Inc. Bioactive compounds for treatment of cancer and neurodegenerative diseases
CN102256494A (zh) * 2008-12-17 2011-11-23 阿纳科制药公司 (s)-3-氨甲基-7-(3-羟基-丙氧基)-3h-苯并[c][1,2]氧杂硼杂环戊-1-醇的多晶型物
WO2010075286A1 (en) 2008-12-24 2010-07-01 University Of Washington MOLECULAR ACTIVATORS OF THE Wnt/β-CATENIN PATHWAY
WO2010097675A1 (en) 2009-02-27 2010-09-02 Dhanuka Laboratories Ltd. An improved preparation process for cefpodoxime proxetil
US20100292185A1 (en) 2009-05-12 2010-11-18 Burns Christopher J Beta-lactamase inhibitors
EP2440050A4 (en) 2009-06-08 2013-04-03 California Capital Equity Llc TRIAZINE DERIVATIVES AND THEIR THERAPEUTIC APPLICATION
JP2013500974A (ja) 2009-07-28 2013-01-10 アナコール ファーマシューティカルズ，インコーポレイテッド 三置換ホウ素含有分子
US20120329770A1 (en) 2010-02-26 2012-12-27 Gary Igor Dmitrienko Cephalosporin derivatives useful as beta-lactamase inhibitors and compositions and methods of use thereof
AU2011235227B2 (en) 2010-03-31 2016-09-08 Millennium Pharmaceuticals, Inc. Derivatives of 1-amino-2-cyclopropylethylboronic acid
US20110288063A1 (en) 2010-05-19 2011-11-24 Naeja Pharmaceutical Inc. Novel fused bridged bicyclic heteroaryl substituted 6-alkylidene penems as potent beta-lactamase inhibitors
JP5603487B2 (ja) 2010-06-10 2014-10-08 テクニオン リサーチ アンド ディベラップメント ファウンデイション リミテッド ヨウ化物の調製のためのプロセス
KR102205755B1 (ko) 2010-08-10 2021-01-22 렘펙스 파머수티클스 인코퍼레이티드 고리형 보론산 에스터 유도체의 결정 형태
DK2632927T3 (en) 2010-10-26 2016-04-11 Mars Inc Boronates AS ARGINSASEINHIBITORER
TW201221518A (en) 2010-11-18 2012-06-01 Glaxo Group Ltd Compounds
EP2487159A1 (en) 2011-02-11 2012-08-15 MSD Oss B.V. RorgammaT inhibitors
EP2508506A1 (en) 2011-04-08 2012-10-10 LEK Pharmaceuticals d.d. Preparation of sitagliptin intermediates
WO2013033461A1 (en) 2011-08-31 2013-03-07 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
WO2013053372A1 (en) 2011-10-13 2013-04-18 Therabor Pharmaceuticals Boronic acid inhibitors of beta-lactamases
WO2013056163A1 (en) 2011-10-14 2013-04-18 The Regents Of The University Of California Beta-lactamase inhibitors
JP6129203B2 (ja) 2011-12-22 2017-05-17 アレス トレーディング ソシエテ アノニム α−アミノボロン酸誘導体、選択性免疫プロテアソーム阻害剤
CA2862710A1 (en) 2012-01-09 2013-07-18 University Of Tromso Therapeutic boron-containing compounds
EP2615080A1 (en) 2012-01-12 2013-07-17 LEK Pharmaceuticals d.d. Preparation of Optically Pure ß-Amino Acid Type Active Pharmaceutical Ingredients and Intermediates thereof
US20150119363A1 (en) 2012-02-15 2015-04-30 Rempex Pharmaceuticals, Inc.. Methods of treating bacterial infections
US9156858B2 (en) 2012-05-23 2015-10-13 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
PT2928898T (pt) 2012-12-07 2021-07-05 Venatorx Pharmaceuticals Inc Inibidores de beta-lactamase
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
JP2016509594A (ja) 2013-01-04 2016-03-31 レンペックス・ファーマシューティカルズ・インコーポレイテッド ボロン酸誘導体及びその治療的使用
JP6324409B2 (ja) 2013-01-04 2018-05-16 レンペックス・ファーマシューティカルズ・インコーポレイテッド ボロン酸誘導体及びその治療的使用
US8999885B2 (en) 2013-01-09 2015-04-07 General Electric Company Methods of activating charcoal resulting from biomass gasification
JP6346904B2 (ja) 2013-01-10 2018-06-20 ベナトルクス ファーマシューティカルズ，インク． ベータ−ラクタマーゼ阻害剤
WO2014151958A1 (en) 2013-03-14 2014-09-25 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
RU2637946C2 (ru) 2013-03-15 2017-12-08 Интрексон Корпорейшн Борсодержащие диацилгидразины
US9687497B1 (en) 2014-05-05 2017-06-27 Rempex Pharmaceuticals, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
FI3604316T3 (fi) 2014-05-05 2024-02-29 Melinta Therapeutics Inc Boronaattisuolojen synteesi
AU2015264418A1 (en) 2014-05-19 2016-11-10 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
RU2686740C2 (ru) 2014-06-11 2019-04-30 Венаторкс Фармасьютикалс, Инк. Ингибиторы бета-лактамазы
US9511142B2 (en) * 2014-06-11 2016-12-06 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
EA201692301A1 (ru) 2014-07-01 2017-06-30 Ремпекс Фармасьютикалз, Инк. Производные бороновой кислоты и их терапевтическое применение
WO2016065282A1 (en) 2014-10-24 2016-04-28 The Regents Of The University Of Michigan Nasal formulation, nasal kit, and method for enhancing nasal nitric oxide (no) levels
US20180051041A1 (en) 2015-03-17 2018-02-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
JP6945452B2 (ja) 2015-04-24 2021-10-06 レンペックス・ファーマシューティカルズ・インコーポレイテッド 細菌感染症の処置方法
UA124464C2 (uk) 2016-06-30 2021-09-22 Кьюпекс Біофарма, Інк. Похідні боронової кислоти та їх терапевтичні застосування

Also Published As

Publication number Publication date
RS60310B1 (sr) 2020-07-31
LT3412676T (lt) 2020-07-27
BR112013003045B1 (pt) 2021-08-31
KR102087313B1 (ko) 2020-03-11
WO2012021455A1 (en) 2012-02-16
CA2807546A1 (en) 2012-02-16
JP7227282B2 (ja) 2023-02-21
EP2603514A4 (en) 2014-10-29
JP6266978B2 (ja) 2018-01-24
US20230277571A1 (en) 2023-09-07
JP2013535502A (ja) 2013-09-12
HUE040086T2 (hu) 2019-02-28
CY2020019I1 (el) 2020-11-25
US20250064838A1 (en) 2025-02-27
MY188960A (en) 2022-01-14
LUC00168I2 (lt) 2024-07-01
CO6680667A2 (es) 2013-05-31
SMT202000248T1 (it) 2020-07-08
DK3412676T3 (da) 2020-05-04
US20160220591A1 (en) 2016-08-04
US9694025B2 (en) 2017-07-04
JP2017052794A (ja) 2017-03-16
US20180207183A1 (en) 2018-07-26
US20120040932A1 (en) 2012-02-16
CA2807546C (en) 2022-08-23
BR112013003045A2 (pt) 2016-06-14
CN103180328B (zh) 2016-10-26
KR20130099923A (ko) 2013-09-06
JP6854861B2 (ja) 2021-04-07
US20220125813A1 (en) 2022-04-28
IL224564A (en) 2017-02-28
LTC3412676I2 (lt) 2022-09-12
SG187757A1 (en) 2013-03-28
CY2020020I1 (el) 2020-11-25
KR20190066084A (ko) 2019-06-12
KR20200028043A (ko) 2020-03-13
AU2011289615A1 (en) 2013-03-21
RU2013104951A (ru) 2014-09-20
KR101987091B1 (ko) 2019-06-10
KR102205755B1 (ko) 2021-01-22
PL2603514T3 (pl) 2019-04-30
EP2603514A1 (en) 2013-06-19
RU2599791C2 (ru) 2016-10-20
US20180214465A1 (en) 2018-08-02
NO2019014I1 (no) 2019-03-28
HRP20200741T1 (hr) 2020-10-16
US10639318B2 (en) 2020-05-05
NZ607354A (en) 2015-01-30
US9296763B2 (en) 2016-03-29
PT3412676T (pt) 2020-05-19
EP2603514B1 (en) 2018-07-18
PT2603514T (pt) 2018-11-09
EP3412676B1 (en) 2020-02-12
ES2691468T3 (es) 2018-11-27
DK2603514T3 (en) 2018-10-29
US20130345172A1 (en) 2013-12-26
CL2013000399A1 (es) 2013-08-23
US20190076449A1 (en) 2019-03-14
US10183034B2 (en) 2019-01-22
LTPA2020521I1 (lt) 2020-08-10
US11684629B2 (en) 2023-06-27
JP6602742B2 (ja) 2019-11-06
US8680136B2 (en) 2014-03-25
MX2013001517A (es) 2013-04-29
AU2011289615B2 (en) 2015-05-07
MY198204A (en) 2023-08-11
EP3666778B1 (en) 2021-11-10
LTPA2020519I1 (lt) 2020-08-10
US20200222434A1 (en) 2020-07-16
EP3666778A1 (en) 2020-06-17
CY2020019I2 (el) 2020-11-25
NO2019013I1 (no) 2019-03-28
US12171772B2 (en) 2024-12-24
US10004758B2 (en) 2018-06-26
JP2021073212A (ja) 2021-05-13
MX348653B (es) 2017-06-21
CY1123208T1 (el) 2020-11-25
CY2020020I2 (el) 2020-11-25
HUS1900018I1 (hu) 2019-05-28
CN103180328A (zh) 2013-06-26
EP3412676A1 (en) 2018-12-12
ES2789177T3 (es) 2020-10-26
US20180071325A1 (en) 2018-03-15
JP2020002178A (ja) 2020-01-09
LUC00169I2 (lt) 2024-07-01
US11090319B2 (en) 2021-08-17
HUE048859T2 (hu) 2020-08-28
HUS1900017I1 (hu) 2019-05-28
US10172874B2 (en) 2019-01-08
PL3412676T3 (pl) 2021-04-06

Similar Documents

Publication Publication Date Title
LTPA2020519I1 (lt) Cikliniai borono rūgšties dariniai, jų gamybos būdas ir terapinis panaudojimas
LT2894151T (lt) Imidazolino dariniai, jų gamybos būdai ir jų naudojimas medicinoje
IL239120A0 (en) Devices and methods for connecting implantable devices to wireless energy
LT2770994T (lt) 1h-pirazolo[3,4-b]piridinai ir jų terapiniai panaudojimai
EP2941247A4 (en) Boronic acid derivatives and therapeutic uses thereof
LT2895653T (lt) Tirpios celiuliozės gamybos būdas, tirpi celiuliozė ir būdo panaudojimas
EP2931751A4 (en) THERAPEUTIC CD47 ANTIBODIES
DK2934197T3 (da) Røgfrit, oralt tobaksprodukt og fremstilling deraf
LT3023102T (lt) Ibat inhibitoriai, skirti kepenų ligų gydymui
EP2587156A4 (en) Glowplug, production method thereof and heating device
DK2384731T3 (da) Medicinsk behandlingsvogn
HUE054621T2 (hu) Gyógyászáti készítmény, kezelési eljárások és alkalmazásaik
SMT201500233B (it) Metodi per rilevare anticorpi anti-farmaco
BR112012032494A2 (pt) produto, utilizaçõa e método de produção de um produto
LT2459459T (lt) Talpyklė, talpyklės gamybos būdai ir sandariai uždaroma talpyklė
DK2819974T3 (da) Gødningsmiddel, anvendelse deraf og fremstillingsfremgangsmåde
HRP20251576T1 (hr) Povećanje bioraspoloživosti lijekova u terapiji naltreksonom
EP2594281A4 (en) INSULIN LIPID COMPLEX, MANUFACTURING METHOD AND PREPARATION THEREFROM
EP2546226A4 (en) 1-METHOXYL-2,6,10-TRIMETHYL-1,3,5,9-UNDEC-TETRAEN AND METHOD FOR THE PRODUCTION AND USE THEREOF
EP2634184A4 (en) C-Argylglucoside derivative, process for its preparation and use thereof
PL2912039T3 (pl) Pochodne kamptotecyny, sposób ich otrzymywania i zastosowanie
LTC2734522I2 (lt) 4-imidazopiridazin-1-il-benzamidai ir 4-imidazotriazin-1-il-benzamidai, kaip btk inhibitoriai
SI3412676T1 (sl) Ciklični derivati estra borove kisline, postopek za njihovo pripravo in njihove terapevtske uporabe
FR2966066B1 (fr) Procede de moulage en modele perdu
PL398891A1 (pl) Sposób wytwarzania 4',5,6,7-tetrahydroksyflawanonu oraz 4',5,7,8-tetrahydroksyflawanonu